Los Angeles Capital Management LLC Has $967,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Los Angeles Capital Management LLC grew its position in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 344.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 930,132 shares of the biotechnology company's stock after purchasing an additional 720,672 shares during the period. Los Angeles Capital Management LLC owned approximately 0.81% of Coherus BioSciences worth $967,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in CHRS. Nisa Investment Advisors LLC increased its stake in Coherus BioSciences by 2,672.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company's stock valued at $36,000 after buying an additional 19,912 shares during the period. TIAA Trust National Association bought a new stake in shares of Coherus BioSciences in the 2nd quarter worth $47,000. Bayesian Capital Management LP bought a new position in Coherus BioSciences during the first quarter valued at about $56,000. Price T Rowe Associates Inc. MD boosted its stake in Coherus BioSciences by 32.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company's stock valued at $74,000 after buying an additional 7,608 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Coherus BioSciences during the first quarter worth about $94,000. Institutional investors and hedge funds own 72.82% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Robert W. Baird reduced their price objective on shares of Coherus BioSciences from $8.00 to $4.00 and set an "outperform" rating for the company in a research report on Friday, November 8th. HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Coherus BioSciences in a research report on Thursday, November 7th. StockNews.com cut Coherus BioSciences from a "buy" rating to a "hold" rating in a report on Saturday, October 19th. Finally, UBS Group lowered Coherus BioSciences from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $4.00 to $1.50 in a research note on Friday, August 16th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Coherus BioSciences presently has an average rating of "Moderate Buy" and an average price target of $6.13.

Coherus BioSciences Stock Performance

Shares of NASDAQ:CHRS traded down $0.03 during mid-day trading on Friday, hitting $0.74. The stock had a trading volume of 3,005,811 shares, compared to its average volume of 2,675,845. The company's 50 day moving average is $0.94 and its 200-day moving average is $1.41. Coherus BioSciences, Inc. has a 12-month low of $0.66 and a 12-month high of $3.70. The company has a market cap of $85.72 million, a PE ratio of -9.30 and a beta of 0.69.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.